Skip to main content

Most Popular


Steroid injections worsen knee arthritis

Nov 30, 2022

Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease.

Read Article

Low Dose IL-2 Therapy in Sjögren’s

Nov 29, 2022

There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.

Read Article

Avoid Abatacept in RA patients with a history of cancer?

The management of rheumatoid arthritis patients with a history of cancer continues to be an area of concern for rheumatologists. General recommendations are to treat patients with a history of solid organ cancer as no different to any other RA patient.

Read Article

Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines

In the wake of the 2016 American Academy of Ophthalmology Guidelines, rheumatologists have dutifully reduced the dose of hydroxychloroquine (HCQ) take by patients with systemic lupus erythemato

Read Article
Vegetarian diet food nutrition

Will a vegetarian diet and exercise actually help RA disease activity?

Nov 25, 2022

In research that surprised many at ACR Convergence 2022, a Dutch program targeting a whole food plant-based diet, physical activity, and stress management has shown benefit in DAS28 rheumatoid arthritis disease activity measures, just as ACR guidelines regarding exercise, diet and other integrati

Read Article
Lungs breathing

RA-ILD takes centre stage

Interstitial Lung Disease (ILD) is common in rheumatoid arthritis (RA), occurring in approximately 8% of RA patients. It is associated with a poor prognosis, with a median survival of 3 years.

Read Article
lupus SLE

Tyk2 Inhibition Effective in SLE

Nov 28, 2022

Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.

Read Article
syringe, pill, DMARD, Treatment, therapy

Emerging and exciting treatments in RA: ACR22 preview

Rheumatoid arthritis treatment has come leaps and bounds in recent decades. Gone are the days of gold injections, chemical synovectomies, and physician-mandated bedrest (heaven forbid). Though the marketplace for RA treatments is becoming ever more crowded, there are still unmet needs.

Read Article
Best of

ACR Best Abstracts - Day 3

Nov 14, 2022

The last day was jammed with important reports and research including the late breaking abstracts. 


Read Article
EULAR19.abstract.jpg (keep)

ACR Best Abstracts - Day 1

Nov 12, 2022

The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).


Read Article

Rheumatology Roundup: ACR22

Nov 21, 2022

On Thursday, November 21, 2022, Dr. Arthur Kavanaugh and Dr. Jack Cush reviewed the best and most interesting data and sessions presented at ACR22 in Philadelphia, PA. These are the research abstracts discussed:

Read Article
RheumNow Podcast square

ACR 2022 Appraisal, Praise & Critique (11.18.2022)

Nov 18, 2022

It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle. 

I loved the city, but not the convention center (not easy to navigate). 

Read Article
lupus SLE

Dual target blockade may be better than one in SLE

Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus (SLE). However, outcomes of therapies within the same class (i.e. BAFF-inhibitor) when evaluated in randomised controlled trials (RCTs) have been inconsistent.

Read Article


Dec 01, 2022

A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX. 

Read Article
cancer search news magnify

Xeljanz Cancer Risks Detailed

MedPage Today
Dec 07, 2022

The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.

Read Article
RA, hands, MCP, deformity

New 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis

Nov 10, 2022

The updated 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) were initially presented by Dr. Josef Smolen at EULAR 2022, and are now in press delineating the most recent developments and perspectives in RA treatment.

Read Article
PMR spotlight

ACR22: Polymyalgia Rheumatica in the Spotlight

One of the enduring legacies of ACR 2022 for me will be the emphasis on polymyalgia rheumatica (PMR). Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run in this space.

Read Article
ACR Best

ACR Best Abstracts - Day 2

Nov 13, 2022

Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.

Here are the RheumNow faculty selections for #ACRbest abstracts today:


Read Article

Familial Mediterranean Fever mimics

Familial Mediterranean fever (FMF) is an inherited autoinflammatory disease characterized by recurrent attacks of fever and acute inflammation of the membranes lining the abdomen, joints and lungs. These attacks are often short-lasting, around 1-3 days.

Read Article

Proposed Cancer Screening for Inflammatory Myositis Patients

Nov 12, 2022

Today's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer.  Abstract 0002

Read Article